Mauna Kea Technologies disclosed the total number of voting rights and shares comprising its share capital as of June 30, 2026. The filing, made in accordance with Article L233-8-II of the Commercial Code and Article 223-16 of the General Regulations of the AMF, provides transparency regarding the company's ownership structure.

The company reported a total of 194,473,901 shares in circulation. The total number of voting rights stood at 195,560,768 on both a gross and net basis. The gross total serves as the basis for calculating thresholds under AMF regulations, while the net total represents voting rights exercisable in General Meeting, excluding shares with suspended voting rights.

Share Capital and Voting Rights Details

The following table outlines the share capital and voting rights distribution as of June 30, 2026:

Regulatory Definitions

(1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Article 223-11 of the General Regulations of the AMF, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.

(2) The net number of voting rights (or voting rights "exercisable in General Meeting") is calculated without considering the shares with suspended voting rights. It is published for proper public information in accordance with the AMF recommendation of July 17, 2007.

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio, the real-time in vivo cellular imaging platform. The company is listed on Euronext Growth Paris under the ticker ALMKT.